Intra-Cellular Therapies, Inc. (ITCI)
USD 131.87
(0.0%)
USD 131.87
(0.0%)
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2023 | 728.29 Million USD | -3.51% |
| 2022 | 754.78 Million USD | 54.06% |
| 2021 | 489.92 Million USD | -31.7% |
| 2020 | 717.31 Million USD | 185.57% |
| 2019 | 251.18 Million USD | -29.68% |
| 2018 | 357.2 Million USD | -24.24% |
| 2017 | 471.48 Million USD | 21.23% |
| 2016 | 388.9 Million USD | -19.67% |
| 2015 | 484.1 Million USD | 269.23% |
| 2014 | 131.11 Million USD | 241.0% |
| 2013 | 38.44 Million USD | 93.96% |
| 2012 | 19.82 Million USD | 0.0% |
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2024 Q1 | 747.03 Million USD | 2.57% |
| 2024 Q3 | 1.32 Billion USD | 0.3% |
| 2024 Q2 | 1.32 Billion USD | 76.77% |
| 2023 Q4 | 728.29 Million USD | 1.48% |
| 2023 FY | 728.29 Million USD | -3.51% |
| 2023 Q1 | 722.15 Million USD | -4.32% |
| 2023 Q2 | 713.6 Million USD | -1.18% |
| 2023 Q3 | 717.66 Million USD | 0.57% |
| 2022 Q3 | 781.99 Million USD | -3.68% |
| 2022 Q1 | 868.58 Million USD | 77.29% |
| 2022 FY | 754.78 Million USD | 54.06% |
| 2022 Q4 | 754.78 Million USD | -3.48% |
| 2022 Q2 | 811.9 Million USD | -6.52% |
| 2021 Q4 | 489.92 Million USD | -12.04% |
| 2021 Q2 | 625.69 Million USD | -7.23% |
| 2021 FY | 489.92 Million USD | -31.7% |
| 2021 Q3 | 556.97 Million USD | -10.98% |
| 2021 Q1 | 674.48 Million USD | -5.97% |
| 2020 Q4 | 717.31 Million USD | -7.0% |
| 2020 FY | 717.31 Million USD | 185.57% |
| 2020 Q3 | 771.29 Million USD | 74.92% |
| 2020 Q2 | 440.93 Million USD | -8.38% |
| 2020 Q1 | 481.24 Million USD | 91.59% |
| 2019 FY | 251.18 Million USD | -29.68% |
| 2019 Q2 | 309.86 Million USD | -9.65% |
| 2019 Q3 | 280.52 Million USD | -9.47% |
| 2019 Q4 | 251.18 Million USD | -10.46% |
| 2019 Q1 | 342.97 Million USD | -3.98% |
| 2018 Q3 | 385.58 Million USD | -6.43% |
| 2018 Q1 | 445.63 Million USD | -5.48% |
| 2018 FY | 357.2 Million USD | -24.24% |
| 2018 Q4 | 357.2 Million USD | -7.36% |
| 2018 Q2 | 412.07 Million USD | -7.53% |
| 2017 Q2 | 349.53 Million USD | -6.11% |
| 2017 Q1 | 372.29 Million USD | -4.27% |
| 2017 Q4 | 471.48 Million USD | 41.08% |
| 2017 FY | 471.48 Million USD | 21.23% |
| 2017 Q3 | 334.19 Million USD | -4.39% |
| 2016 Q3 | 542.57 Million USD | 21.22% |
| 2016 Q4 | 388.9 Million USD | -28.32% |
| 2016 Q1 | 463.66 Million USD | -4.22% |
| 2016 FY | 388.9 Million USD | -19.67% |
| 2016 Q2 | 447.6 Million USD | -3.46% |
| 2015 Q3 | 513.12 Million USD | 140.45% |
| 2015 Q4 | 484.1 Million USD | -5.66% |
| 2015 Q2 | 213.4 Million USD | -10.0% |
| 2015 Q1 | 237.12 Million USD | 80.86% |
| 2015 FY | 484.1 Million USD | 269.23% |
| 2014 Q4 | 131.11 Million USD | -4.72% |
| 2014 Q1 | 146.63 Million USD | 281.38% |
| 2014 Q2 | 141.34 Million USD | -3.61% |
| 2014 FY | 131.11 Million USD | 241.0% |
| 2014 Q3 | 137.6 Million USD | -2.64% |
| 2013 Q2 | 49.00 USD | -98.8% |
| 2013 FY | 38.44 Million USD | 93.96% |
| 2013 Q4 | 38.44 Million USD | -18.77% |
| 2013 Q1 | 4070.00 USD | -99.98% |
| 2013 Q3 | 47.33 Million USD | 96604075.51% |
| 2012 Q4 | 19.82 Million USD | 0.0% |
| 2012 FY | 19.82 Million USD | 0.0% |
| Name | Total Assets | Total Assets Difference |
|---|---|---|
| ANI Pharmaceuticals, Inc. | 904.42 Million USD | 19.474% |
| Aquestive Therapeutics, Inc. | 57.41 Million USD | -1168.409% |
| Collegium Pharmaceutical, Inc. | 1.14 Billion USD | 36.299% |
| Dynavax Technologies Corporation | 997.09 Million USD | 26.958% |
| Esperion Therapeutics, Inc. | 205.79 Million USD | -253.892% |
| Cosmos Health Inc. | 66.29 Million USD | -998.558% |
| Pacira BioSciences, Inc. | 1.57 Billion USD | 53.741% |
| PainReform Ltd. | 9.93 Million USD | -7234.29% |
| Sunshine Biopharma, Inc. | 27.34 Million USD | -2563.166% |
| Sunshine Biopharma, Inc. | 27.34 Million USD | -2563.166% |
| SCYNEXIS, Inc. | 128.41 Million USD | -467.155% |
| Safety Shot Inc | 12.7 Million USD | -5630.464% |
| China SXT Pharmaceuticals, Inc. | 23.12 Million USD | -3049.104% |
| Alpha Teknova, Inc. | 128.58 Million USD | -466.383% |
| Embecta Corp. | 1.21 Billion USD | 40.028% |
| Bright Green Corporation | 17.4 Million USD | -4084.871% |
| Journey Medical Corporation | 76.84 Million USD | -847.696% |
| Procaps Group, S.A. | 460.18 Million USD | -58.261% |
| Theratechnologies Inc. | 77.76 Million USD | -836.485% |
| Harrow Health, Inc. | 311.75 Million USD | -133.611% |
| Sonoma Pharmaceuticals, Inc. | 14.89 Million USD | -4790.183% |
| Biofrontera Inc. | 27.93 Million USD | -2507.386% |
| DURECT Corporation | 45.18 Million USD | -1511.664% |
| Supernus Pharmaceuticals, Inc. | 1.4 Billion USD | 48.31% |
| Cronos Group Inc. | 1.13 Billion USD | 35.791% |
| OptiNose, Inc. | 107.72 Million USD | -576.044% |
| Ironwood Pharmaceuticals, Inc. | 471.07 Million USD | -54.603% |
| Kala Pharmaceuticals, Inc. | 55.94 Million USD | -1201.712% |
| RedHill Biopharma Ltd. | 23.04 Million USD | -3060.024% |
| Organogenesis Holdings Inc. | 460.02 Million USD | -58.316% |
| Guardion Health Sciences, Inc. | 11.91 Million USD | -6010.792% |
| Cumberland Pharmaceuticals Inc. | 81.77 Million USD | -790.597% |
| Radius Health, Inc. | 1.71 Billion USD | 57.557% |
| Universe Pharmaceuticals INC | 53.28 Million USD | -1266.74% |
| ProPhase Labs, Inc. | 91.92 Million USD | -692.254% |
| Phibro Animal Health Corporation | 982.18 Million USD | 25.849% |
| Procaps Group S.A. | 460.18 Million USD | -58.261% |
| Alvotech | 950.09 Million USD | 23.345% |
| TherapeuticsMD, Inc. | 43.3 Million USD | -1581.625% |
| Viatris Inc. | 47.68 Billion USD | 98.473% |
| Rockwell Medical, Inc. | 52.17 Million USD | -1295.923% |
| Aytu BioPharma, Inc. | 118.09 Million USD | -516.703% |
| SIGA Technologies, Inc. | 254.83 Million USD | -185.789% |
| Tilray Brands, Inc. | 4.33 Billion USD | 83.201% |
| Lifecore Biomedical, Inc. | 273.7 Million USD | -166.09% |
| Shineco, Inc. | 84.17 Million USD | -765.17% |
| PetIQ, Inc. | 868.22 Million USD | 16.117% |
| Regencell Bioscience Holdings Limited | 8.43 Million USD | -8530.917% |
| Incannex Healthcare Limited | 17.04 Million USD | -4172.277% |
| Neurocrine Biosciences, Inc. | 3.25 Billion USD | 77.601% |
| Alimera Sciences, Inc. | 153.52 Million USD | -374.385% |
| Silver Spike Investment Corp. | 88.57 Million USD | -722.224% |
| Assertio Holdings, Inc. | 286.41 Million USD | -154.276% |
| Shuttle Pharmaceuticals Holdings, Inc. | 5.95 Million USD | -12136.682% |
| Petros Pharmaceuticals, Inc. | 33.79 Million USD | -2054.987% |
| Clever Leaves Holdings Inc. | 31.24 Million USD | -2231.066% |
| Cyclo Therapeutics, Inc. | 13.24 Million USD | -5397.588% |
| Avadel Pharmaceuticals plc | 261.12 Million USD | -178.906% |
| Hempacco Co., Inc. | 18.04 Million USD | -3936.423% |
| Talphera, Inc. | 20.39 Million USD | -3470.949% |
| Alvotech | 950.09 Million USD | 23.345% |
| Eagle Pharmaceuticals, Inc. | 406.16 Million USD | -79.312% |
| Lantheus Holdings, Inc. | 1.65 Billion USD | 55.892% |
| Currenc Group, Inc. | 141.49 Million USD | -414.731% |
| Kamada Ltd. | 351.96 Million USD | -106.92% |
| Indivior PLC | 1.95 Billion USD | 62.675% |
| Evoke Pharma, Inc. | 7.06 Million USD | -10203.321% |
| Flora Growth Corp. | 23.62 Million USD | -2982.6% |
| Cyclo Therapeutics, Inc. | 13.24 Million USD | -5397.588% |
| Evolus, Inc. | 188.99 Million USD | -285.345% |
| HUTCHMED (China) Limited | 1.27 Billion USD | 43.092% |
| Amphastar Pharmaceuticals, Inc. | 1.51 Billion USD | 51.861% |
| Akanda Corp. | 8.83 Million USD | -8138.638% |